Helius Medical Technologies Inc has a consensus price target of $14.5 based on the ratings of 4 analysts. The high is $24 issued by Roth MKM on March 5, 2024. The low is $5 issued by Roth Capital on August 23, 2022. The 3 most-recent analyst ratings were released by Roth MKM, Maxim Group, and Roth Capital on March 5, 2024, December 20, 2022, and August 23, 2022, respectively. With an average price target of $10 between Roth MKM, Maxim Group, and Roth Capital, there's an implied 1594.92% upside for Helius Medical Technologies Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Helius Medical Tech (NASDAQ:HSDT) was reported by Maxim Group on October 16, 2024. The analyst firm set a price target for $0.00 expecting HSDT to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.
The latest analyst rating for Helius Medical Tech (NASDAQ:HSDT) was provided by Maxim Group, and Helius Medical Tech downgraded their hold rating.
There is no last upgrade for Helius Medical Tech
The last downgrade for Helius Medical Technologies Inc happened on October 16, 2024 when Maxim Group changed their price target from N/A to N/A for Helius Medical Technologies Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Helius Medical Tech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Helius Medical Tech was filed on October 16, 2024 so you should expect the next rating to be made available sometime around October 16, 2025.
While ratings are subjective and will change, the latest Helius Medical Tech (HSDT) rating was a downgraded with a price target of $0.00 to $0.00. The current price Helius Medical Tech (HSDT) is trading at is $0.59, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.